Skip to main content

Table 1 Baseline demographic and clinical characteristics of subjects

From: Comparison of adherence between fixed and unfixed topical combination glaucoma therapies using Japanese healthcare/pharmacy claims database: a retrospective non-interventional cohort study

Variable

Fixed combination (N = 309)

Unfixed combination (N = 329)

n

Percentage or mean ± SD

n

Percentage or mean ± SD

Sex, male

170

55.0

188

57.1

Age (years)

309

56.5 ± 10.2

329

57.1 ± 10.2

Body weight (kg)

210

61.8 ± 12.5

219

61.6 ± 11.0

Height (cm)

218

163.9 ± 9.2

226

164.4 ± 8.9

Body mass index (kg/m2)

210

22.9 ± 3.5

219

22.7 ± 3.1

Smoking

 Yes

33

10.7

32

9.7

 No

178

57.6

193

58.7

Medication for other indications

 Yes

63

20.4

74

22.5

 No

146

47.2

149

45.3

Fasting blood glucose (mg/dL)

200

97.0 ± 17.4

213

97.8 ± 15.4

HbA1c (NGSP) (%)

205

5.6 ± 0.6

216

5.6 ± 0.5

Urine glucose

 Negative (−)

208

67.3

221

67.2

 Positive (≥±)

4

1.3

2

0.6

Urine protein

 Negative (−)

192

62.1

207

62.9

 Positive (≥±)

24

7.8

19

5.8

Antihypertensive drug

 Yes

46

14.9

52

15.8

 No

163

52.8

171

52.0

Systolic blood pressure (mm Hg)

218

119.9 ± 15.5

226

120.3 ± 16.2

Diastolic blood pressure (mm Hg)

218

74.5 ± 11.3

226

75.6 ± 11.2

Total cholesterol (mg/dL)

64

207.3 ± 32.0

53

201.7 ± 35.9

Triglycerides (mg/dL)

217

107.9 ± 64.8

226

101.3 ± 66.6

HDL cholesterol (mg/dL)

217

64.6 ± 16.7

226

65.0 ± 16.9

LDL cholesterol (mg/dL)

217

124.4 ± 26.9

226

126.2 ± 31.2

Aspartate transaminase (U/L)

217

23.7 ± 9.3

226

23.0 ± 8.8

Alanine aminotransferase (U/L)

217

23.3 ± 14.6

226

23.5 ± 13.6

γ-GTP (U/L)

216

41.4 ± 49.1

226

37.6 ± 41.6

Common comorbidities

 Hypertension

92

29.8

110

33.4

 Cancer

90

29.1

114

34.7

 Hyperlipidemia

87

28.2

111

33.7

 Diabetes mellitus

85

27.5

97

29.5

 Insomnia

44

14.2

44

13.4

 Liver disorder

43

13.9

44

13.4

 Asthma or COPD

41

13.3

66

20.1

 Gastrointestinal ulcer

38

12.3

41

12.5

 Atherosclerosis or PAOD

31

10.0

38

11.6

 Anemia

30

9.7

33

10.0

 Coronary artery disease

26

8.4

33

10.0

 Heart failure

22

7.1

35

10.6

Locations

 8 regions

  Hokkaido

7

2.3

3

0.9

  Tohoku

14

4.5

6

1.8

  Kanto

176

57.0

207

62.9

  Chubu

38

12.3

37

11.2

  Kinki

38

12.3

36

10.9

  Chugoku

10

3.2

9

2.7

  Shikoku

2

0.6

2

0.6

  Kyushu

24

7.8

29

8.8

 Areas

  East Japan

210

68.0

220

66.9

  West Japan

99

32.0

109

33.1

 City size

  Tokyo and all GODMCs

255

82.5

289

87.8

  Other than GODMCs

54

17.5

40

12.2

  1. HBA1c hemoglobin A1c, NGSP National Glycohemoglobin Standardization Program, HDL high-density lipoprotein, LDL low-density lipoprotein, COPD chronic obstructive pulmonary disease, γ-GTP γ-glutamyl transpeptidase, PAOD peripheral arterial occlusive disease, GODMCs government ordinance-designed major cities